Cargando…

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?

Resistant hypertension is, by definition, a challenge to most physicians treating hypertension. Renal sympathetic denervation has shown promising early results in treating this condition. The SYMPLICITY HTN-3 is the most recent trial to report the effects of this technique on resistant hypertension....

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Hitesh C, Hayward, Carl, Di Mario, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2014
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104384/ https://www.ncbi.nlm.nih.gov/pubmed/25054126 http://dx.doi.org/10.5339/gcsp.2014.15

Ejemplares similares

Renal denervation after the symplicity HTN-3 trial
por: Warchoł-Celińska, Ewa, et al.
Publicado: (2014)

Renal Denervation after Symplicity HTN-3: An Update
por: Persu, Alexandre, et al.
Publicado: (2014)

Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension
por: Fadl Elmula, Fadl Elmula M., et al.
Publicado: (2015)

Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry
por: Mahfoud, Felix, et al.
Publicado: (2017)

Retrospective morphometric study of the suitability of renal arteries for renal denervation according to the Symplicity HTN2 trial criteria
por: Schönherr, Elisabeth, et al.
Publicado: (2016)

SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold?
por: Staessen, Jan A, et al.
Publicado: (2014)

Renal denervation for the management of resistant hypertension
por: Patel, Hitesh C, et al.
Publicado: (2015)

Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design
por: Böhm, Michael, et al.
Publicado: (2020)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

AMBITION: An important piece in the therapeutic puzzle of pulmonary arterial hypertension
por: Said, Karim
Publicado: (2015)

Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry
por: Said, Karim
Publicado: (2014)

The Beginning of the End—The Knell of Sectarianism in Medicine
por: Rochester, DeLancey
Publicado: (1902)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
por: ElGuindy, Ahmed
Publicado: (2016)

Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
por: Suwaidi, Jassim Al
Publicado: (2016)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry
por: Schmieder, Roland E, et al.
Publicado: (2022)

Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE
por: Mahfoud, Felix, et al.
Publicado: (2023)

Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials
por: Kirtane, Ajay J., et al.
Publicado: (2023)

Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study
por: Saxena, Manish, et al.
Publicado: (2021)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
por: Yacoub, Magdi H, et al.
Publicado: (2013)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

ARCTIC: Additional proof against antiplatelet adjusted therapy
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE
por: Raynaud, Christophe M., et al.
Publicado: (2013)

Off-pump coronary artery bypass grafting (OPCABG): the beginning of the end?
por: Taggart, David
Publicado: (2013)

PCI versus CABG in patients with complex coronary artery disease: Time for reconciliation?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

TOPCAT misses its primary endpoint: Should spironolactone be abandoned in HFpEF?
por: ElGuindy, Ahmed M.
Publicado: (2013)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan
por: Gogas, Bill D., et al.
Publicado: (2015)

Biocorrodible metals for coronary revascularization: Lessons from PROGRESS-AMS, BIOSOLVE-I, and BIOSOLVE-II
por: Bouchi, Yasir H., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m4hp67qv9n08gf4ghr4r4dcn9p